Clinical trials are an essential tool in modern medicine, they are research investigations in which people voluntarily participate in studies for new treatments and interventions to prevent, diagnose or manage blood disorders. Clinical trials are crucial for the development of new medical treatments and help determine if new medicines are effective, safe or better than the current treatments available and aim to answer the following questions in a controlled environment:
Does the treatment work? Is the treatment safe - does it have significant side effects? Is the treatment better that other treatments already available? If better, does it have less side effects? Does it work faster? Is it more cost-effective than other treatments?
Please visit Participate in a clinical trial for details on how to participate in a trial, or contact us for further information. Summaries of PBI's previous clinical trials can be found in our archived projects. Our current active clinical trials are outlined below, or for a fact sheet about clinical trials, see here.
A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M) Read more
An observational study of patients with Microangiopathic Thrombocytopenia by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network. Read more
Study the safety and pharmacokinetics of escalating doses of BTCT4465A as a single agent and combined with Atezolizumab in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. Read more
Study of the safety, pharmacokinetics, and clinical activity of PRN1008, an oral BTK inhibitor, in patients with relapsed Immune Thrombocytopenic Purpura. Read more
Study of ME-401 in subjects with Follicular Lymphoma after failure of two or more prior systemic therapies. Read more
To compare the efficacy and safety of Luspatercept (ACE-536) versus Epoetin Alfa for the treatment of anaemia due to I PSS-R, very low, low or intermediate risk Myelodysplastic syndromes in ESA Naïve subjects who require red blood cell transfusions. Read more
Study of Venetoclax and Dexamethasone compared with Pomalidomide and Dexamethasone in subjects with t(11;14)-positive relapsed or refractory Multiple Myeloma. Read more
To assess the efficacy and safety of BIVV009 in patients with primary cold agglutinin disease without a recent history of blood transfusion. Read more
A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors. Read more
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML) Read more
A phase 1/2a study to evaluate safety, pharmacokinetic and pharmacodynamic dose escalation and expansion study of PXS-5505 in patients with primary, postpolycythemia vera or post-essential thrombocythemia myelofibrosis Read more
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Read more
This is a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma Read more
This study consists of two parts to explore BGB-16673 recommended dosing. Read more
This is an extension study to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies. Read more
The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib. Read more
This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, and effect on QoL/PRO of efgartigimod PH20 SC treatment in adult patients with primary ITP. Read more